AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1(Cancelled).

2(Previously Presented). The method according to claim 4, wherein said compound of formula I and said selective estrogen receptor modulator are delivered in a single composition.

3(Previously Presented). The method according to claim 4, wherein said compound of formula I and said selective estrogen receptor modulator are delivered separately.

4(Currently Amended). A method of inducing contraception comprising delivering to a female of child-bearing age a composition comprising a compound of formula I in a regimen which involves delivering a pharmaceutically effective amount of one or more selective estrogen receptor modulator selected from the group consisting of EM-800, EM-652, raloxifene hydrochloride, arzoxifene, lasofoxifene, droloxifene, tamoxifen citrate, 4-hydroxytamoxifen citrate, clomiphene citrate, toremifene citrate, pipendoxifene, idoxifene, levormeloxifene, centchroman, nafoxidene, and bazedoxifene to said female, wherein formula I is:



I

wherein:

R^1 and R^2 are joined to form $-CH_2(CH_2)_nCH_2-$;

n is 3 or 4 ~~or 5~~;

R^3 is H;

R^4 is H;

R^5 is a five membered heterocyclic ring having 1 heteroatom selected from the group consisting of O, S, SO, and NR^6 and having one CN ~~or two~~ and one ~~independent~~ substituents selected from the group consisting of H, halogen, ~~CN,~~ C_1 to C_3 alkyl, and CSR^D;

R^D is NH_2;

R^6 is H or C_1 to C_3 alkyl;

Q^1 is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

5(Previously Presented). The method according to claim 4, wherein said compound is delivered at a daily dosage of about 0.1 to about 50 mg.

6(Previously Presented). The method according to claim 4, wherein said regimen comprises delivering said composition daily for 1 to about 21 days, wherein said regimen is a cycle which is repeated monthly.

7(Previously Presented). The method according to claim 4, wherein said selective estrogen receptor modulator is delivered at a daily dosage of about 0.2 to about 100 mg.

8(Cancelled).

9(Currently Amended). The method according to Claim 4, wherein R^5 is the five membered ring having the structure:



U is O, S, or NR^6;

X' is selected from the group consisting of halogen, CN, and $CSNH_2$;

Y' is H.

10-13(Cancelled).

14(Previously Presented). The method according to claim 4, wherein said compound is selected from the group consisting of 4-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile, 4-Methyl-5-(1,2-dihydro-2-thioxospiro[cyclohexane-1,3-[3H]-indol]-5-yl)-2-thiophenethioamide, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1H-pyrrole-2-carbonitrile, 5-(2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-3-thiophenecarbonitrile, 5-(1,2-Dihydro-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-2-thiophenecarbonitrile, 5-(5-Chloro-2-thienyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-3-furancarbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl-2-thiophenecarbonitrile, 4-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-4-methyl-2-thiophenecarbonitrile, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-2-thiophenecarbonitrile, and a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

15-43(Cancelled).

44(New). A method of inducing contraception comprising delivering to a female of child-bearing age a composition comprising a compound of formula I in a regimen which involves delivering a pharmaceutically effective amount of one or more selective estrogen receptor modulator selected from the group consisting of EM-800, EM-652, raloxifene hydrochloride, arzoxifene, lasofoxifene, droloxifene, tamoxifen citrate, 4-hydroxytamoxifen citrate, clomiphene citrate, toremifene citrate, pipendoxifene, idoxifene, levormeloxifene, centchroman, nafoxidene, and bazedoxifene to said female, wherein formula I is:



I

wherein:

R^1 and R^2 are joined to form $-CH_2(CH_2)_nCH_2-$;

n is 3 or 4;

R^3 is H;

R^4 is H;

R^5 is a five membered heterocyclic ring having 1 O or S heteroatom and having one CN and one substituent selected from the group consisting of H, halogen, C_1 to C_3 alkyl, and CSR^D;

R^D is NH_2;

R^6 is H or C_1 to C_3 alkyl;

Q^1 is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

45(New). The method according to claim 44, wherein said compound of formula I and said selective estrogen receptor modulator are delivered in a single composition.

46(New). The method according to claim 44, wherein said compound of formula I and said selective estrogen receptor modulator are delivered separately.

47(New). The method according to claim 44, wherein said compound is delivered at a daily dosage of about 0.1 to about 50 mg.

48(New). The method according to claim 44, wherein said regimen comprises delivering said composition daily for 1 to about 21 days, wherein said regimen is a cycle which is repeated monthly.

49(New). The method according to claim 44, wherein said selective estrogen receptor modulator is delivered at a daily dosage of about 0.2 to about 100 mg.

50(New). A method of inducing contraception comprising delivering to a female of child-bearing age a composition comprising a compound of formula I in a regimen which involves delivering a pharmaceutically effective amount of one or more selective estrogen receptor modulator selected from the group consisting of EM-800, EM-652, raloxifene hydrochloride, arzoxifene, lasofoxifene, droloxifene, tamoxifen citrate, 4-hydroxytamoxifen citrate, clomiphene citrate, toremifene citrate, pipendoxifene, idoxifene, levormeloxifene, centchroman, nafoxidene, and bazedoxifene to said female, wherein formula I is:



I

wherein:

R^1 and R^2 are joined to form $-CH_2(CH_2)_nCH_2-$;

n is 3 or 4;

R^3 is H;

R^4 is H;

R^5 is a five membered heterocyclic ring having 1 NR^6 heteroatom and having one CN and one substituent selected from the group consisting of H, halogen, C_1 to C_3 alkyl, and CSR^D;

R^D is NH_2;

R^6 is H or C_1 to C_3 alkyl;

Q^1 is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

51(New). The method according to claim 50, wherein said compound of formula I and said selective estrogen receptor modulator are delivered in a single composition.

52(New). The method according to claim 50, wherein said compound of formula I and said selective estrogen receptor modulator are delivered separately.

53(New). The method according to claim 50, wherein said compound is delivered at a daily dosage of about 0.1 to about 50 mg.

54(New). The method according to claim 50, wherein said regimen comprises delivering said composition daily for 1 to about 21 days, wherein said regimen is a cycle which is repeated monthly.

55(New). The method according to claim 50, wherein said selective estrogen receptor modulator is delivered at a daily dosage of about 0.2 to about 100 mg.